Prevalence of depression, anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram

Trial Profile

Prevalence of depression, anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2012

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Anxiety disorders; Depression; Impulse control disorders; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 18 Aug 2011 Planned End Date changed to 20 May 2009.
    • 18 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top